NCT06390852 2025-11-04Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled